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Systematic Review of Randomized Controlled Trials
of Patch Angioplasty Versus Primary Closure and
Different Types of Patch Materials During Carotid
Endarterectomy
Kittipan Rerkasem1 and Peter M. Rothwell,2 1Department of Surgery, Faculty of Medicine, Chiang Mai University,
Chiang Mai, Thailand, 2Stroke Prevention Research Unit, University of Oxford, Oxford, UK.
OBJECTIVE: Patch angioplasty during carotid endarterectomy (CEA) can reduce the risk of periopera-
tive stroke or late carotid artery recurrent stenosis and subsequent ischaemic stroke. We aimed to update
our previous systematic review of randomized controlled trials (RCTs) of routine or selective carotid patch
angioplasty compared with CEA with primary closure, and of different materials used for carotid patch
angioplasty.
METHODS: We identified new RCTs published during 2002–2010 by searching Medline, Embase and
the Cochrane Stroke Group Trials Register. We also hand-searched six relevant journals. Pooled estimates
of treatment effects combined with our previous review (1966–2001) were calculated on the basis of 
a weighted estimate of the odds ratio (OR) with the Peto method.
RESULTS: Twenty-three eligible RCTs were identified in both periods. Ten RCTs involving 2,157 opera-
tions compared primary closure with routine patch closure. Patch closure significantly reduced the com-
bined risk of perioperative stroke and later stroke during long-term follow-up [OR = 0.49, 95% confidence
interval (CI) = 0.27–0.90, p = 0.001; 7 RCTs]. Patching also reduced the risks of perioperative arterial occlu-
sion (OR = 0.18, 95% CI = 0.08–0.41, p < 0.0001; 7 RCTs) and recurrent stenosis during long-term follow-
up (OR = 0.24, 95% CI = 0.17–0.34, p < 0.001; 8 RCTs).
CONCLUSION: Meta-analysis of relatively small RCTs suggests that carotid patch angioplasty reduces
the combined perioperative and long-term risk of stroke and the risk of restenosis. More data are needed.
[Asian J Surg 2011;34(1):32–40]
Key Words: carotid endarterectomy, patch angioplasty, primary closure, synthetic patching, venous
patching
Introduction
Carotid endarterectomy (CEA) has been shown in large
randomized controlled trials (RCTs) to reduce the risk of
stroke in selected patients with internal carotid artery
stenosis.1,2 For example, carotid patch angioplasty with a
vein or synthetic patch is believed by some surgeons to be
preferable to primary closure,3 because it can reduce the
risk of early and late recurrent stenosis, and consequently,
the long-term risk of ipsilateral ischaemic stroke. Restenosis
of > 50% detected on duplex ultrasound scans occurs in
6–36% of patients during long-term follow-up,3 with most
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occurring in the first 2 years after surgery. However, the
value of reducing the rate of recurrent stenosis is uncer-
tain, because the risk for symptomatic recurrent stenosis
appears to be much lower than for all recurrent stenosis.4
Patching might also be beneficial in patients with
marked intimal thickening of the distal internal carotid
artery, by smoothing flow in the transitional zone from
the CEA area to the residual distal artery, and is also rec-
ommended in patients with an elongated or kinked carotid
artery, to maintain lumen diameter and avoid postopera-
tive occlusion.3 However, patching might also be associ-
ated with increased perioperative stroke risk due to longer
carotid occlusion time, and with complications caused by
the need for two suture lines instead of one, or the patch
material, including postoperative occlusion, arterial rup-
ture, infection, or pseudoaneurysm formation.5,6 Patching
is also more technically demanding than primary closure.3
RCTs are therefore necessary to determine reliably the
overall balance of risk and benefit.
There is also considerable debate over the choice of
patch material. Vein patches, harvested from the saphe-
nous or jugular veins, are favoured by some, on the basis
that they are easily available, easy to handle, have greater
resistance to infection, result in greater luminal diameter,
and are less thrombogenic.3 However, there may be mor-
bidity associated with vein harvesting, such as neuralgia,
haemorrhage, and infection. Synthetic material, such as
Dacron or polytetrafluoroethylene (PTFE), is favoured by
others, who believe that it offers a lower risk for patch
rupture and aneurysm dilatation.6 It also spares the mor-
bidity associated with saphenous vein harvesting, and
leaves the vein intact for future use as a conduit for coro-
nary or peripheral bypass grafting. However, there is also
uncertainty about whether one type of synthetic material
is better than another.5,6
Given the uncertainty implied by the variation in use
of patching and patch type in routine clinical practice, we
previously systematically reviewed RCTs that compared
routine or selective patching with primary closure, or the
efficacy of different patch materials, published between
1966 and 2001.5–7 We have reported reduced risks of peri-
operative and long-term risks of stroke and reduced rates
of restenosis with routine patching versus primary clo-
sure. However, the number of eligible trials was small,
methodology was inconsistent, and statistical power was
limited due to the small size of all the individual trials.5
There were also insufficient trial data on which to base
judgements about differences in outcome between patch
types.6 We have therefore updated our systematic review
to include trials published up to 2010.
Methods
We sought to identify all RCTs that compared primary
closure with routine (patching attempted in all patients)
or selective carotid patch angioplasty with any type of
patch, and trials in which one type of patch compared
with another. To identify all relevant trials published
between January 2002 and March 2010, we searched the
Medline and Embase databases, and the Cochrane Con-
trolled Trials Register, using a Medical Subject Headings
strategy initially developed by the Cochrane Controlled
Trials Group; similar to our previous paper (Figure 1).5–7
Furthermore, six journals were hand-searched for the
same period: Annals of Surgery, European Journal of Vascular
and Endovascular Surgery, Stroke, Journal of Vascular Surgery,
Annals of Vascular Surgery and Cardiovascular Surgery. The
reference lists from all relevant trials identified with the
above methods were also searched.
Trials of endarterectomy for symptomatic or asymp-
tomatic carotid stenosis were eligible. Trials in which allo-
cation to different treatment regimens was not adequately
concealed (e.g. allocation by alternation, date of birth,
hospital number, day of the week, or with an open random
number list) were included in the main analyses, but were
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Medline & Embase 2002–2010
3,953 titles screened
625 abstracts screened
87 references eligible for full review
27 references analyse for full text
Hand-searching
6 journals and
review reference lists
8 trials eligible for study
Figure 1. Strategy and result of the literature search.
also analysed separately from those trials in which allo-
cation concealment was secured, to check that no bias 
was being introduced by foreknowledge of treatment 
allocation.9
We aimed to extract from each trial the number of
patients originally allocated to each treatment group to
allow intention-to-treat analysis. Outcomes were 30-day
risk of any stroke, fatal stroke, ipsilateral ischaemic stroke,
all-cause mortality, and combined stroke and death. Local
complications, such as arterial rupture, acute carotid
thrombosis, wound infection, cranial nerve injury, return
to the operating room for any reason, or development of
recurrent stenosis > 50% were also recorded.
One reviewer (KR) did the search, selected which trials
to include in the review, and assessed the methodological
quality of each trial. Data on the number of outcome
events in all patients originally randomized were sought
to allow intention-to-treat analysis. All extracted data were
cross-checked by a second reviewer (PMR). In addition,
details about the patients included in the trial, inclusion
and exclusion criteria, comparability of the treatment and
control groups for important prognostic factors, type 
of patch, type of anaesthetic, use of shunts, and use of
antiplatelet therapy during follow-up were also extracted.
If any of these data were not available from the publica-
tion, further information was sought by correspondence
with the trialists.
Analysis of outcomes was performed per artery rather
than per patient, because this was how most trials pre-
sented their results. All of the trials included some patients
who had undergone bilateral CEA, and in most trials, the
artery was randomized to a particular procedure rather
than to the patient. In these trials, it was therefore possi-
ble for a patient to have primary closure on one side and
carotid patching on the other. In the reporting of these
trials, the results were given for each artery randomized,
rather than for each individual patient. This makes sense
for arterial complications such as haemorrhage or occlu-
sion, for ipsilateral events and for complications within
30 days of surgery, in as much as most patients waited at
least this long between the first and second operations.
However, it is not ideal for patient-related, long-term clin-
ical outcome events, such as death or any stroke.
Proportional risk reductions were calculated on the
basis of a weighted estimate of the odds ratio (OR) with
the Peto method. All outcome events assessed were rare;
therefore, the ORs quoted are similar to the relative risks.
Heterogeneity between trial results was tested with the
standard χ2 test.
Results
Twenty-three eligible RCTs were identified. Ten RCTs
that involved 2,157 operations compared primary closure
with routine patch closure, and 13 trials with 2,083 oper-
ations compared different patch materials. Compared
with our previous review, we included three new trials10–12
that compared patching with primary closure. One of
these trials was published prior to 2001,12 but was missed
by our previous literature search; partly because it was
published in a book rather than in an electronically
indexed journal. We also included two new trials13,14 that
compared synthetic with venous patching, and three 
trials8,15,16 that compared Dacron and other synthetic
materials. One of these trials was also published prior to
2001,16 and was also missed by our previous literature
search5,6 because it was published in a book. In keeping
with the previous review, one unpublished trial was
excluded because of excessive rates of crossovers between
randomized groups.5
The methodological quality of the 23 included RCTs
varied. For example, inadequate methods of randomiza-
tion and blinding were used in several trials, and this
could have biased the results.9 Most trials used sealed
envelopes as the method of randomization, but in one
case, the envelopes were not numbered or were opaque,17
and in two trials, allocation was made on the basis of the
patient’s hospital number18 or social security number.19
Most of the patients in all of the trials received anti-
platelet or anticoagulant drugs in the long term after sur-
gery, and all trials used heparin during the operation.
However, one trial used heparin reversal at the end of sur-
gery in 30% of patients with synthetic closure but in no
patients with vein closure.19 Data on heparin reversal were
not available from any of the other trials. During follow-
up, recurrent arterial stenosis was assessed with duplex
ultrasound scanning in all trials, with the addition of
intravenous digital subtraction angiography in two.5,18
Trials of routine patch versus primary closure
Ten trials compared primary closure with routine 
patch closure, of which three used only saphenous vein
patches,17,18,20 three used synthetic patches,10,11,21 and
four used both vein and synthetic (PTFE or Dacron)
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patches.12,22–24 One trial included a group that was allo-
cated to obligate patching without randomization20; this
group of patients was not included in the analyses. Thus,
data from 10 trials (1,967 patients, 2,157 operations) were
included in this review.17,18,20–24 Three trials excluded
patients if the arteries were thought too small to close pri-
marily. Myers et al20 excluded 38 arteries if the vessels were
< 5 mm in diameter, Katz and Kohl19 excluded one of 110
arteries < 3.5 mm in diameter, and AbuRahma et al22
excluded 12 of 399 arteries < 4 mm in diameter. A sum-
mary of all meta-analysis results is provided in Table 1.
The overall risk for stroke was 2.5%, and for combined
stroke and death it was 3.0%. There was a borderline sig-
nificant excess risk of perioperative stroke with primary
closure versus patching (p = 0.06). However, although our
previous meta-analysis showed a 61% reduction in the
odds of operative stroke or death [OR = 0.39, 95% confi-
dence interval (CI) 0.20–0.78, p = 0.007] in patients allo-
cated patching, with virtually no heterogeneity between
trials (Figure 2),5 the two more recent trials included in
this updated review (including 750 operations) both
reported nonsignificant trends towards an increased oper-
ative risk of stroke and death with patch closure. There
were no obvious methodological differences between the
new and the previous trials that might have explained the
different trends.
The two most recent trials did not report data on ipsilat-
eral perioperative stroke, perioperative arterial occlusion,
or return to the operating room. Based on the earlier trials
only, patching significantly reduced the risks of each of
these outcomes (Table 1), but effect sizes might have been
smaller if data from the more recent trials had been avail-
able. There was no significant difference between patching
and primary closure for risk of death or arterial rupture.
None of the arterial ruptures was associated with a fatal or
major stroke. Episodes of local infection and cranial nerve
palsy were too few to enable conclusions to be drawn.
Eight trials, including both of the more recent trials,
followed up patients for longer than 30 days.10,11,17,18,20–22,24
Fifty-three arteries (3.1%; 27 patch, 26 primary closure)
were lost to follow-up. For the purposes of analysis, these
patients were assumed to be event free. Patching was asso-
ciated with a significant reduction in risk for any stroke
(p = 0.02). Patching was also associated with a reduced
long-term risk of ipsilateral stroke (p = 0.001) and com-
bined stroke or death (p = 0.004), but these outcomes were
not reported in the two most recent trials. However, data
from these trials were available for restenosis, with patching
Table 1. Summary estimates of treatment effect from all meta-analysed outcomes from 10 trials comparing patch closure with 
primary closure that were included in the review*
Outcome
No. of trials Patch closure Primary closure
OR 95% CI p
(reference no.) events/cases (%) events/cases (%)
Perioperative 30-d results
Ipsilateral stroke 7 (17,18,20–24) 10/687 (1.5) 23/514 (4.5) 0.31 0.15–0.63 0.001
All death 9 (10–12,17,18,20−22,24) 5/986 (0.5) 6/883 (0.7) 0.62 0.18–2.09 0.44
Fatal stroke 7 (11,17,18,20−22,24) 1/783 (0.1) 2/658 (0.3) 0.47 0.05–4.56 0.52
Any stroke 8 (10,11,17,18,20−22,24) 18/936 (1.9) 27/833 (3.2) 0.57 0.31–1.03 0.06
Stroke or death 8 (11,17,18,20−24) 22/936 (2.4) 31/833 (3.7) 0.58 0.33–1.01 0.06
Return to theatre 7 (17,18,20−24) 8/731 (1.1) 17/550 (3.1) 0.35 0.16–0.79 0.01
Arterial occlusion 7 (10,18,20−24) 4/794 (0.5) 20/641 (3.1) 0.18 0.08–0.41 < 0.0011
Cranial nerve injury 4 (11,20−22) 13/581 (2.2) 14/466 (3.0) 0.78 0.36–1.69 0.53
Perioperative and 
long-term follow-up
Ipsilateral stroke 6 (17,18,20−22,24) 10/641 (1.6) 24/500 (4.8) 0.32 0.16–0.63 0.001
All death 7 (10,17,18,20−22,24) 70/723 (9.7) 73/609 (12.0) 0.78 0.54–1.12 0.18
Fatal stroke 6 (17,18,20−22,24) 1/577 (0.2) 4/442 (0.9) 0.27 0.05–1.60 0.15
Any stroke 7 (10,17,18,20−22,24) 17/723 (2.4) 28/609 (4.6) 0.49 0.27–0.90 0.02
Stroke or death 6 (17,18,20−22,24) 75/577 (13) 91/442 (20.6) 0.59 0.42–0.84 0.004
Restenosis 8 (10,11,17,18,20−22,24) 40/921 (4.3) 110/798 (13.8) 0.24 0.17–0.34 < 0.01
*Data were not available for all outcomes from all trials, and there was significant loss to follow-up. OR = odds ratio; CI = confidence interval.
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being associated with a substantial reduction in risk
(p < 0.00001). No pseudoaneurysm was found on follow-
up of at least 1 year in 1,719 arteries. There was no signif-
icant heterogeneity in treatment effect between trials in
any of the above meta-analyses, except for long-term
restenosis (p = 0.006).
Trials of vein versus synthetic patch materials
Nine trials6,13,14,21–23,25–27 compared vein closure with
PTFE closure in a total of 1,506 operations (Table 2). Four
trials compared saphenous vein harvested from the groin
with synthetic patches,6,21,23,25 two trials14,27 used saphe-
nous vein from the ankle; one trial22 alternately used vein
from the jugular and from the saphenous vein at the
ankle; one trial13 used vein from the external jugular vein;
and one trial26 did not specify a site. In all trials, the oper-
ations were performed under general anaesthesia and
most were also performed with shunting. The overall peri-
operative risks for stroke, and stroke and death were 
low (1.8% and 2.4%, respectively). No significant differ-
ence was seen in the perioperative risks for all strokes,
ipsilateral stroke, combined stroke and death, or overall
mortality. Wound infection was not significantly more
common in the vein group compared with the synthetic
patch group because of increased risk for groin wound
infection. Repeat operation for any reason occurred in
2.6% of patients (33 of 1,263), and showed a nonsignifi-
cant trend toward being more common in the synthetic
patch group (p =0.13). Most repeat operations were because
of patch rupture (1 in the PTFE group, 2 in the vein
group) or wound haemorrhage (2.3%, 29 of 1,263). Two of
the three patch ruptures were fatal, with one in each
group. There was a nonsignificant tendency for wound
haematoma to be more common in the synthetic group
(p = 0.17). Cranial nerve palsy occurred in 4.7% of patients
(24 of 717). There was no suggestion that it was more
common in either group. The absolute risk for arterial
occlusion was 0.6% (6 of 1,068), with a nonsignificant excess
in arteries patched with synthetic material (p = 0.24). Two
trials19,23 did not follow up patients for at least 1 year. In
the seven remaining trials, there was no significant differ-
ence between PTFE and vein patching for risk of stroke
(p = 0.49), ipsilateral stroke (p = 0.33), death (p = 0.59), or
combined stroke and death (p = 0.82). However, CIs were
wide in each analysis. Seventy-three arteries (6.3%) became
restenosed or occluded during follow-up, with no trend
favouring synthetic or vein patching (p = 0.93). In one
artery with a PTFE patch, an infected false aneurysm
developed at 7 months, which was successfully excised.
There were no other late graft infections.
Previous review
Study
Patching Primary closure
Stroke/death
De 198717
Eikelboom 198818
Lord 198923
Ranaboldo 199324
Katz 199421
Myers 199420
AbuRahma 199622
Subtotal
Subsequent RCTs
Mannheim 200511
AI-Rawi 200610
Subtotal
Total
95% CI
0.02–52.82
0.14–3.11
0.10–1.55
0.04–5.73
0.01–8.57
0.11–0.93
0.20–0.78
0.26–9.56
0.36–3.64
0
OR (95% CI)
0.48–3.31
0.33–1.01
0/62
3/66
No data available
3/96
1/43
0/46
6/264
13/577
3/206
6/153
9/359
22/936
0/64
4/60
7/91
2/44
1/48
9/135
23/442
2/216
6/175
8/391
31/833
OR
Significance/
heterogeneity
1.03
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0.39
0.50
0.34
0.33
0.39
1.58
1.15
1.26
0.58
1 2
p = 0.560 (het)
p = 0.060 (sig)
p = 0.900 (het)
p = 0.007 (sig)
p = 0.770 (het)
p = 0.640 (sig)
Figure 2. Meta-analysis of perioperative risk of stroke/death after carotid endarterectomy, comparing patching and primary closure
in randomized controlled trials before and after 2001. OR = odds ratio; CI = confidence interval.
Trials of Dacron versus other synthetic materials
Meta-analysis of the four trials that compared Dacron and
other synthetic patches (Table 3) showed that Dacron was
associated with a higher risk of perioperative combined
stroke and transient ischaemic attack (p=0.03) and resteno-
sis at 30 days (p =0.004); a borderline significant excess risk
of perioperative stroke (p = 0.07); and a nonsignificant
increased risk of perioperative carotid thrombosis (p = 0.1).
During the perioperative period and subsequent follow-up
of > 1 year, there were significantly more strokes (p = 0.03),
stroke/death (p = 0.02), and arterial restenoses (p < 0.001)
with Dacron compared with other synthetic materials,
but the number of outcomes was small and the signifi-
cance of this finding is uncertain. There was no signifi-
cant heterogeneity in treatment effect between trials in
any of the above meta-analyses (Table 3), except for long-
term restenosis (p = 0.03) or death (p = 0.008).
Discussion
Our results show a potentially clinically important reduction
in favour of routine patching versus primary closure in
terms of short-term and long-term risks of ipsilateral stroke
and acute occlusion and long-term recurrent stenosis.
However, the results of these RCTs might not be completely
reliable, because of small size, lack of true intention-to-
treat analysis, and significant losses to follow-up. Our
previous meta-analysis showed a 61% reduction in the odds
of operative stroke or death (OR = 0.39, 95% CI 0.20–0.78,
p = 0.007) in patients allocated patching with virtually no
heterogeneity between trials (Figure 2).5 However, the two
more recent trials included in this updated review (including
750 operations), both reported nonsignificant trends
towards an increased operative risk of stroke and death with
patch closure. There were no obvious methodological dif-
ferences between the new trials and the previous trials that
might have explained the different trends. The updated
meta-analysis showed only a borderline significant benefit
for patching in terms of procedural risk of stroke and death
(Figure 2), although still consistent with a clinically impor-
tant benefit from patch closure. Nevertheless, given the
uncertainty about conclusions based on meta-analyses of
small trials, a single large trial of patching versus primary
closure is still required to provide reliable evidence.
Table 2. Summary estimates of treatment effect from all meta-analysed outcomes from nine trials comparing vein with synthetic
patch angioplasty that were included in the review*
Outcome
No. of trials Synthetic Vein closure
OR 95% CI p
(reference no.) events/cases (%) events/cases (%)
Perioperative 30-d results
Ipsilateral stroke 5 (6,19,22,23,27) 8/406 (2.0) 3/391 (0.8) 2.05 0.66–6.38 0.21
All death 8 (6,13,14,19,22,25−27) 4/684 (0.6) 10/685 (1.5) 0.52 0.20–1.34 0.18
Fatal stroke 6 (6,19,22,25−27) 0/562 (0.0) 4/560 (0.7) 0.27 0.04–1.66 0.16
Any stroke 8 (6,13,14,19,22,25−27) 13/684 (1.9) 12/685 (1.8) 1.09 0.51–2.31 0.82
Stroke or death 6 (6,19,22,25−27) 15/562 (2.7) 12/560 (2.1) 1.25 0.58–2.66 0.57
Return to theatre 7 (6,19,22,23,25−27) 21/635 (3.3) 12/628 (1.9) 1.72 0.85–3.47 0.13
Arterial rupture 6 (6,19,22,23,25,27) 1/541 (0.2) 2/527 (0.4) 0.68 0.13–3.54 0.65
Wound infection 3 (19,25,26) 4/336 (1.2) 10/337 (3.0) 0.38 0.12–1.23 0.11
Cranial nerve injury 4 (14,22,25,27) 13/361 (3.6) 11/356 (3.1) 1.19 0.53–2.71 0.67
Perioperative and 
long-term follow-up
Ipsilateral stroke 4 (6,22,27,30) 17/389 (4.4) 12/387 (3.1) 1.45 0.69–3.07 0.33
All death 7 (6,13,14,22,26,27,30) 46/579 (7.9) 52/588 (8.8) 0.89 0.59–1.36 0.59
Pseudoaneurysm 4 (6,22,27,30) 1/389 (0.3) 14/387 (3.6) 0.09 0.02–0.49 0.005
Any stroke 7 (6,13,14,22,26,27,30) 28/579 (4.8) 24/588 (4.1) 1.22 0.70–2.13 0.49
Infection 2 (6,27) 1/118 (0.1) 0/118 (0.0) 2.8 0.11–69.42 0.54
Stroke or death 5 (6,22,26,27,30) 57/457 (12.5) 56/463 (12.1) 1.05 0.70–1.56 0.82
Restenosis 7 (6,13,14,22,26,27,30) 36/573 (6.3) 37/575 (6.4) 1.0 0.61–1.57 0.93
*Data were not available for all outcomes from all trials, and there was significant loss to follow-up. OR = odds ratio; CI = confidence interval.
■ ARTERIOTOMY CLOSURE IN CAROTID SURGERY ■
ASIAN JOURNAL OF SURGERY VOL 34 • NO 1 • JANUARY 2011 37
■ RERKASEM & ROTHWELL ■
38 ASIAN JOURNAL OF SURGERY VOL 34 • NO 1 • JANUARY 2011
However, patching did appear to reduce significantly the
risk of acute occlusion and long-term recurrent stenosis,
compared with primary closure. However, acute oc-
clusion, although undesirable, is not always associated
with stroke, and recurrent stenosis detected at routine
duplex scanning is often not of obvious clinical impor-
tance, and is associated with a lower risk of neurological
symptoms than is primary stenosis.31
The results of trials of patching versus primary closure
are likely to be dependent on the types of patients
included. Most surgeons agree that carotid patching
sometimes has a role in CEA, because they are faced with
situations in which this type of closure is unavoidable or
positively desirable (e.g. artery with very narrow internal
diameter or very long plaque),22 although it is unclear
how frequently such situations arise, or how narrow an
artery should be before it must be patched. Only three tri-
als in this review excluded narrow arteries on the grounds
that they must be patched. In the other trials, crossover
from primary closure to patching was required in a few
patients, because the artery was deemed too narrow for
primary closure. There is divided opinion on how often
patching is required; some surgeons use it all the time,
others use it rarely or never.32 The trials of patch versus no
patch included in this review tested the policy of routinely
patching all arteries against a policy of never patching in
patients with no definite indication for a patch. A policy
of selective patching of only those arteries thought to
require a patch at the time of operation compared with no
patching has not been tested in RCTs. It is possible that,
if patching is effective, its benefit might be at least partly
restricted to tortuous or very narrow arteries. It was not
possible to test this hypothesis, because the results of the
trials were not reported according to degree of narrowing
of the artery. In one nonrandomized study that compared
outcome in 188 patients with selective patching versus 65
with primary closure, there was no evidence of a differ-
ence in early or late risk of stroke.33
Despite more than 2,000 patients randomized, there
were still insufficient data to enable definite conclusions
about the optimal patch type. There were no obvious dif-
ferences in the risk for stroke or death in patients who
received synthetic or vein patches, either perioperatively
or during long-term follow-up, or evidence to support the
belief that synthetic patches are associated with lower risk
for patch rupture. The risk for major arterial complica-
tions such as rupture or infection was low (< 1%) in both
groups, although pseudoaneurysm did occur in 3.6% of
patients with vein patching. However, any trials designed
to detect reliably reduction in risk for rupture with 
Table 3. Summary estimates of treatment effect from all meta-analysed outcomes from four trials comparing Dacron with other syn-
thetic patch angioplasty that were included in the review*
Outcome
No. of trials Dacron Other synthetic 
OR 95% CI p
(reference no.) events/cases (%) events/cases (%)
Perioperative 30-d results
Ipsilateral stroke 2 (15,28) 9/200 (4.5) 2/200 (1) 3.89 0.96–15.73 0.06
All death 4 (8,15,16,28) 3/296 (1.0) 3/303 (1) 1.03 0.30–3.57 0.96
Any stroke/TIA 1 (28) 12/100 (12) 3/100 (3) 4.41 1.20–16.14 0.03
Any stroke 2 (8,28) 7/144 (4.86) 1/151 (0.7) 4.34 0.90–20.90 0.07
Return to theatre 2 (8,28) 7/144 (4.86) 1/151 (0.7) 5.43 0.92–31.90 0.06
Arterial occlusion 1 (28) 5/100 (5) 0/100 (0) 11.58 0.60–212.19 0.10
Early restenosis or occlusion 2 (15,28) 16/200 (8) 2/200 (1) 7.26 1.88–28.04 0.004
Perioperative and long-term 
follow-up
Ipsilateral stroke 1 (15) 3/100 (3) 2/100 (2) 1.52 0.25–9.27 0.65
All death 2 (15,16) 13/152 (8.6) 11/152 (7.2) 1.19 0.52–2.72 0.68
Any stroke 2 (16,28) 9/152 (5.9) 0/152 (0) 10.6 1.34–83.43 0.03
Stroke or death 1 (28) 11/100 (11) 2/100 (2) 6.06 1.31–28.07 0.02
Restenosis 2 (16,28) 30/152 (19.7) 4/152 (2.6) 8.25 3.03–22.49 < 0.01
*Data were not available for all outcomes from all trials. OR = odds ratio; CI = confidence interval; TIA = transient ischaemic attack.
synthetic patches would need to be very large. For exam-
ple, if we assume a long-term risk of rupture of 0.6%, 
> 10,000 arteries would be needed to give a trial 80%
power to detect a 50% reduction in the relative risk of rup-
ture with synthetic patch versus vein patch, and this would
still prevent only one rupture in every 350 operations.
Although there is little reliable evidence to guide sur-
geons as to which patch material to use, synthetic patches
offer the advantage of sparing the morbidity (e.g. poor
wound healing, or pain) and time associated with vein
harvesting, and ensuring that vein is available for future
coronary bypass grafting if required. However, use of
PTFE in patching can increase operation time by several
minutes; mainly because of increased bleeding through
the suture holes. This could be less of a problem with
Dacron patches.34 Dacron might therefore be preferable
to PTFE, although some believe that it carries a greater
risk of thrombosis23 and is more prone to infection.35
Nevertheless, there was some evidence in our study that
other synthetic (e.g. PTFE) patches might be superior to
collagen-impregnated Dacron grafts, in terms of periop-
erative stroke rates and restenosis, but more trials are
required. Recently, AbuRahma has reported a trial of 200
CEA patients, which compared a new modified PTFE
patch (ACUSEAL) with a new ultrathin Dacron graft
patch (Fitnesse).15 The perioperative stroke rate was simi-
lar, as was long-term stroke risk.32
Although autogenous vein patching needs another
harvest procedure and synthetic patching, namely PTFE
and Dacron, this might increase the chance of patch
infection.3 Bovine pericardial patching is another option
to avoid both disadvantages. However, comparisons
between bovine pericardial patching and other synthetic
patching are still limited. Marien and colleagues have
reported a trial that compared bovine perdicardial with
Dacron graft.8 Postoperative stroke rates were compara-
ble, but suture line bleeding at 3 minutes was signifi-
cantly higher in Dacron than the bovine pericardial graft
group (14%, 55% respectively, p <0.001).8 Surgical case series
using bovine pericardial patch have been published,36 but
more RCTs might be helpful.
Finally, it is relevant to note that many surgeons are
now performing eversion CEA as opposed to the standard
arteriotomy technique. With standard CEA, the plaque is
removed via longitudinal arteriotomy, whereas in ever-
sion CEA, endarterectomy is performed by first transect-
ing the proximal internal carotid artery at the bifurcation.
A circumferential plane of endarterectomy is then devel-
oped in the distal internal carotid artery. The adventitia/
residual media are everted, and the tube of atheroma 
is expelled as the dissection plane continues in a cephalad
direction. The bulb of the internal carotid artery is then
re-anastomosed to the bifurcation. This eversion technique
has a lower rate of late stenosis and removes the need for
patching. This was not studied in the present review. In a
systematic review of five trials that involved 2,465 patients,
only CEA with patch angioplasty (with no primary clo-
sure) was considered for comparison with eversion tech-
niques. There was no significant difference in the rate of
perioperative stroke or carotid occlusion between the
treatment groups.37
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